

Technology Advisory Committee C Interests Register

Topic: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (Review of TA669) [ID6167]

Publication Date: 14 December 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Paul Tappenden	Committee Member	Non-financial professional	Professor Tappenden works for ScHARR, the EAG for this topic. He was not involved in the EAG's work.	N/A	19/09/2022	N/A	It was agreed that his declaration would not prevent Professor Tappenden from participating in discussions on this appraisal.